Article

Topical cyclosporine can handle more than dry-eye disease

Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
© 2025 MJH Life Sciences

All rights reserved.